SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study is testing new approaches for children aged 1 to 21 with acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma. We're comparing a new chemotherapy drug, SC-PEG, with a current one, Oncaspar, focusing on side effects and how long the drug stays in the body. We're also studying whether changing treatment based on tiny amounts of cancer cells (called 'minimal residual disease') can improve outcomes. Another part of the study looks at whether giving antibiotics early can prevent serious infections. We'll investigate if vitamin D levels affect bone problems during treatment and collect samples to learn more about these cancers to find better treatments in the future. The overall aim is to improve how we treat these illnesses.
Överblick
Resultat
Resultat från denna studie
Publicerad September 2022Resultaten har publicerats för denna studie.
Vad handlar denna studie om?
This study is like a big research project to find better ways to treat childhood cancers called acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma. These conditions need strong medicines, and we are always trying to make treatments safer and more effective for children and young people. This study specifically focuses on several important areas.
Firstly, we're looking at a new version of a common chemotherapy drug called asparaginase. The new version is called SC-PEG. We want to see how well it works and if it has similar side effects compared to another version called Oncaspar, which is already in use. We're also checking how long SC-PEG stays in the blood, as this could mean fewer injections. By comparing these drugs, we hope to find a version that causes fewer side effects or is easier to give. We're also looking at whether adjusting treatment based on very small amounts of remaining cancer cells (called minimal residual disease or MRD) might help improve the chances of a full recovery for children with ALL.
Secondly, the study is investigating ways to prevent common problems that can happen during cancer treatment. Many children getting chemotherapy are at risk of serious infections, so we're testing if giving antibiotics right from the start can stop these infections. We're also looking at how chemotherapy can affect bones, making them weaker. We want to understand if vitamin D, which helps bones stay strong, plays a role in preventing bone problems like broken bones. Finally, we'll be collecting samples to learn more about these cancers themselves, which could lead to even better treatments for children in the future.
Viktiga punkter
- The study aims to improve treatment for childhood leukaemia and lymphoma.
- It compares a new chemotherapy drug (SC-PEG) with an existing one (Oncaspar).
- Researchers are exploring how to tailor treatment based on tiny amounts of remaining cancer cells.
- The study also investigates ways to prevent serious infections and bone problems during treatment.
- It is open to children and young people aged 1 to 21 years old.
- Participation involves chemotherapy and regular medical checks over about two years.
Vem kan vara berättigad?
To join this study, a child or young person must have been recently diagnosed with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma. They should not have started any major treatment for their cancer yet, apart from some short courses of steroids, a single special injection, or emergency radiation for serious problems.
They cannot join the study if they've already had a lot of steroid treatment in the past month or two, or if they've received any chemotherapy or radiotherapy for a different cancer before. Also, children who have uncontrollable health problems, are pregnant or breastfeeding, or have certain other illnesses like HIV cannot take part. The study is open to both boys and girls aged between 1 year and 21 years old.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Is your child between 1 and 21 years old?
- Has your child been recently diagnosed with ALL or lymphoblastic lymphoma?
- Has your child started little to no treatment for their cancer yet?
- Does your child have any other serious health problems?
- Has your child had chemotherapy or radiation for cancer before?
- Is your child pregnant or breastfeeding (if applicable)?
Vad innebär deltagande?
If you decide to take part, your child will receive anti-cancer medicines called chemotherapy. These will be given in different ways: some by mouth, some into a vein (like a drip), and some as injections into a muscle or directly into the fluid around the spine. The treatment schedule, including which drugs and how much, will depend on whether your child’s leukaemia is considered 'Standard Risk', 'High Risk', or 'Very High Risk', which is decided based on their age and other test results. The full course of treatment usually lasts for about two years.
Throughout the study, doctors will regularly check your child's progress. This involves taking blood, bone marrow, and spinal fluid samples to see how the treatment is working and to look for any side effects. They may also do scans like X-rays, CT scans, or MRI scans. The first part of the treatment, called 'steroid prophase', typically involves a hospital stay. You will have regular visits to the hospital for treatments and check-ups. You can withdraw from the study at any time.
Potentiella risker och fördelar
Platser (8)
- Children's Hospital BostonVerifierat postnummerBoston, USA
- Dana-Farber Cancer InstituteVerifierat postnummerBoston, USA
- Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-PresbyterianVerifierat postnummerNew York, USA
- Montefiore medicinska centrumVerifierat postnummerNew York, USA
- Hasbro Children's HospitalVerifierat postnummerProvidence, USA
- McMaster UniversitetVerifierat postnummerHamilton, Kanada
- Hospital Sainte Justine, University of MontrealVerifierat postnummerMontreal, Kanada
- Centre Hospitalier U. de QuebecVerifierat postnummerQuébec, Kanada
Vanliga frågor
Vad är leukemi?
Leukaemia is a type of cancer that affects blood cells, specifically the white blood cells that fight infection. In leukaemia, these cells grow too quickly and don't work properly.
Vad är kemoterapi?
Chemotherapy is medicine used to kill cancer cells. It can be given in different ways, like by mouth, through a drip into a vein, or as injections.
What is 'minimal residual disease'?
This is a test that can find very tiny amounts of cancer cells that are too small to see under a microscope. Tracking these cells can help doctors decide if treatment needs to be adjusted.
Will my child definitely get the new drug SC-PEG?
The study is comparing SC-PEG with Oncaspar, which is currently used. Your child might receive either, but the doctors will discuss which treatment applies to your child's situation.
What happens if my child doesn't want to continue in the study?
You or your child can decide to leave the study at any time, for any reason. Their medical care will continue as usual, even if they leave the study.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.